Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Clinical Trial ID NCT00621452

PubWeight™ 17.26‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00621452

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010 3.57
2 The basic principles of chimeric antigen receptor design. Cancer Discov 2013 3.28
3 CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012 2.97
4 Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013 2.07
5 Driving CAR T-cells forward. Nat Rev Clin Oncol 2016 1.09
6 Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 2010 0.99
7 Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol 2013 0.98
8 Genetically engineered T cells for the treatment of cancer. J Intern Med 2013 0.83
9 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
10 Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy. Immunotargets Ther 2015 0.75
11 Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer 2015 0.75
Next 100